A multicentre analysis of abiraterone acetate in Canadian patients with metastatic castration-resistant prostate cancer

INTRODUCTON: The COU-AA-301 trial showed that abiraterone acetate (abiraterone), an oral cytochrome p450 CYP17 inhibitor, improved survival for men with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel. To better understand the non-clinical trial experience with ab...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Clayton, Ravinder, Wu, Jackson, Heng, Daniel Y., North, Scott A., Emmenegger, Urban, Hotte, Sebastien, Chi, Kim, Zielinski, Rob, Al-Shamsi, Humaid, Chen, Leo, Eigl, Bernhard
Format: Artigo
Langue:Inglês
Publié: Canadian Medical Association 2014
Sujets:
Original Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4164543/
https://ncbi.nlm.nih.gov/pubmed/25295126
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5489/cuaj.1891
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires